{
  "id": 5796,
  "url": "https://nnemf.org/research/5796-low-energy-amplitude-modulated-electromagnetic-field-exposure-feasibility",
  "title": "Low-energy amplitude-modulated electromagnetic field exposure: Feasibility study in patients with hepatocellular carcinoma.",
  "authors": [
    "Fernanda Capareli",
    "Frederico Costa",
    "Jack A Tuszynski",
    "Micelange C Sousa",
    "Yone de C Setogute",
    "Pablo D Lima",
    "Luciana Carvalho",
    "Elizabeth Santos",
    "Brenda P Gumz",
    "Jorge Sabbaga",
    "Tiago B de Castria",
    "Denis L Jardim",
    "Daniela Freitas",
    "Natally Horvat",
    "Regis O F Bezerra",
    "Leonardo Testagrossa",
    "Tiago Costa",
    "Tatiana Zanesco",
    "Antonio F Iemma",
    "Ghassan K Abou-Alfa"
  ],
  "journal": "Cancer medicine",
  "year": "2023",
  "doi": "10.1002/cam4.5944",
  "pmid": "37184216",
  "abstract": "BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) and poor liver function lack effective systemic therapies. Low-energy electromagnetic fields (EMFs) can influence cell biological processes via non-thermal effects and may represent a new treatment option. METHODS: This single-site feasibility trial enrolled patients with advanced HCC, Child-Pugh A and B, Eastern Cooperative Oncology Group 0-2. Patients underwent 90-min amplitude-modulated EMF exposure procedures every 2-4 weeks, using the AutEMdev (Autem Therapeutics). Patients could also receive standard care. The primary endpoints were safety and the identification of hemodynamic variability patterns. Exploratory endpoints included health-related quality of life (HRQoL), overall survival (OS). and objective response rate (ORR) using RECIST v1.1. RESULTS: Sixty-six patients with advanced HCC received 539 AutEMdev procedures (median follow-up, 30 months). No serious adverse events occurred during procedures. Self-limiting grade 1 somnolence occurred in 78.7% of patients. Hemodynamic variability during EMF exposure was associated with specific amplitude-modulation frequencies. HRQoL was maintained or improved among patients remaining on treatment. Median OS was 11.3 months (95% confidence interval [CI]: 6.0, 16.6) overall (16.0 months [95% CI: 4.4, 27.6] and 12.0 months [6.4, 17.6] for combination therapy and monotherapy, respectively). ORR was 24.3% (32% and 17% for combination therapy and monotherapy, respectively). CONCLUSION: AutEMdev EMF exposure has an excellent safety profile in patients with advanced HCC. Hemodynamic alterations at personalized frequencies may represent a surrogate of anti-tumor efficacy. NCT01686412.",
  "effect": "mixed",
  "evidence": "low",
  "extraction": {
    "studyType": "other",
    "studyTypeLabel": "Other",
    "effectDirection": "mixed",
    "evidenceLabel": "Low",
    "population": "Patients with advanced hepatocellular carcinoma (Child-Pugh A and B; ECOG 0–2)",
    "sampleSize": "66",
    "exposure": "medical device (AutEMdev; amplitude-modulated EMF exposure) · 90-min procedures every 2–4 weeks",
    "confidencePct": "74",
    "peerReviewed": "yes",
    "mainFindings": "In 66 patients receiving 539 procedures (median follow-up 30 months), no serious adverse events occurred during procedures; self-limiting grade 1 somnolence occurred in 78.7% of patients. Hemodynamic variability during exposure was associated with specific amplitude-modulation frequencies. HRQoL was maintained or improved among patients remaining on treatment; median OS was 11.3 months overall and ORR was 24.3%.",
    "outcomes": [
      "Safety (adverse events during procedures)",
      "Hemodynamic variability patterns during EMF exposure",
      "Health-related quality of life (HRQoL)",
      "Overall survival (OS)",
      "Objective response rate (ORR) by RECIST v1.1"
    ],
    "limitations": [
      "Single-site feasibility trial",
      "Patients could also receive standard care (combination therapy vs monotherapy reported)",
      "Exploratory endpoints (HRQoL",
      "OS",
      "ORR)"
    ],
    "keywords": [
      "amplitude-modulated electromagnetic field",
      "low-energy EMF",
      "AutEMdev",
      "Autem Therapeutics",
      "hepatocellular carcinoma",
      "feasibility trial",
      "safety",
      "hemodynamic variability",
      "quality of life",
      "overall survival",
      "objective response rate",
      "RECIST v1.1"
    ],
    "hubs": [],
    "raw": "{\n  \"study_type\": \"other\",\n  \"exposure\": {\n    \"band\": null,\n    \"source\": \"medical device (AutEMdev; amplitude-modulated EMF exposure)\",\n    \"frequency_mhz\": null,\n    \"sar_wkg\": null,\n    \"duration\": \"90-min procedures every 2–4 weeks\"\n  },\n  \"population\": \"Patients with advanced hepatocellular carcinoma (Child-Pugh A and B; ECOG 0–2)\",\n  \"sample_size\": 66,\n  \"outcomes\": [\n    \"Safety (adverse events during procedures)\",\n    \"Hemodynamic variability patterns during EMF exposure\",\n    \"Health-related quality of life (HRQoL)\",\n    \"Overall survival (OS)\",\n    \"Objective response rate (ORR) by RECIST v1.1\"\n  ],\n  \"main_findings\": \"In 66 patients receiving 539 procedures (median follow-up 30 months), no serious adverse events occurred during procedures; self-limiting grade 1 somnolence occurred in 78.7% of patients. Hemodynamic variability during exposure was associated with specific amplitude-modulation frequencies. HRQoL was maintained or improved among patients remaining on treatment; median OS was 11.3 months overall and ORR was 24.3%.\",\n  \"effect_direction\": \"mixed\",\n  \"limitations\": [\n    \"Single-site feasibility trial\",\n    \"Patients could also receive standard care (combination therapy vs monotherapy reported)\",\n    \"Exploratory endpoints (HRQoL, OS, ORR)\"\n  ],\n  \"evidence_strength\": \"low\",\n  \"confidence\": 0.74,\n  \"peer_reviewed_likely\": \"yes\",\n  \"keywords\": [\n    \"amplitude-modulated electromagnetic field\",\n    \"low-energy EMF\",\n    \"AutEMdev\",\n    \"Autem Therapeutics\",\n    \"hepatocellular carcinoma\",\n    \"feasibility trial\",\n    \"safety\",\n    \"hemodynamic variability\",\n    \"quality of life\",\n    \"overall survival\",\n    \"objective response rate\",\n    \"RECIST v1.1\"\n  ],\n  \"suggested_hubs\": []\n}"
  },
  "synthesis": null,
  "synthesisStatus": "pending",
  "originalHref": "https://pubmed.ncbi.nlm.nih.gov/37184216/",
  "sourceUrl": "https://rfsafe.org/mel/paper.php?id=5796",
  "updated": "2026-02-14 08:52:45"
}